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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
mesenchymal stem cell therapy decreased the number of relapses in patients with multiple
sclerosis.
STUDY DESIGN: Review of three randomized controlled trials from 2006-2016.
DATA SOURCES: Two randomized control trials and one case series were found searching
PubMed. The randomized control trials compared the number of relapses of patients undergoing
stem cell therapy against placebo and anti-inflammatory treatment (IV methylprednisolone and
oral prednisone). The case series compared the number of relapses patients experienced before
and after stem cell therapy.
OUTCOMES MEASURED: Clinical outcomes included the number of relapses patients
experienced measured by onset of new neurological symptoms or by the presence of new
gadolinium enhancing lesions (GELs) on MRI.
RESULTS: Li J, Zhang D, Geng T, et al. demonstrated that recurrence frequency was
significantly different between the two groups (p < 0.038).5 After dichotamization of the relapse
data, it was found that for every two patients treated with human umbilical cord derived
mesenchymal stem cells therapy for 6 weeks, 2 or more relapses were prevented when compared
to steroid therapy (NNT = 2). Llufriu S, Sepulveda M, Blanco Y, et al. found a decrease in mean
number of GEL between the BM-MSC group and placebo group (-2.78 + 5.89 vs 3 + 5.36, p =
0.075).6 The relapse frequency data was evaluated as NNT and found that for every patient with
multiple sclerosis treated with bone marrow derived stem cells for 12 months, no additional
relapses will be prevented when compared to the placebo group (NNT = 0). Lu Z, Zhao H, Xu J,
Zhang Z, Zhang X, et al. study suggested that HUC-MSC reduced relapse rate in MS patients by
36.4% at 18 months post treatment compared to before treatment (1.2 + 0.5 vs 3.3 + 0.7, p <
0.05).7
CONCLUSIONS: The results of two RCTs and one case studies showed a decrease in the
number of relapses patients with MS experienced after being treated with MSCs compared to
steroids, placebo, and before therapy.
KEY WORDS: Multiple Sclerosis, mesenchymal stem cell therapy
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INTRODUCTION
Multiple sclerosis (MS) is an autoimmune disease effecting the central nervous system
(CNS). It is characterized by chronic inflammation, demyelination, gliosis (scarring), and
neuronal loss.1 Those affected by MS experience episodes of weakness, numbness and tingling in
their upper extremities along with loss of voluntary control of their limbs along with visual
symptoms and incontinence issues. Patients may experience periods where they recover partial
neuronal function but ultimately progress to permanent disabilities.2 The prevalence of MS
worldwide is 0.1-0.2%.2 It affects approximately 2.5 million people worldwide with 350,000
cases reported in the US alone.2 MS is a chronic disabling disease present throughout the world.
The etiology of MS is not completely understood. Current evidence suggests a genetic
susceptibility to the disease based on twin studies and family history. MS also has an
autoimmune association with HLA-DR2 (human leukocyte antigen) and alleles of IL2RA (the
interleukin-2 receptor alpha gene) and IL7RA (the interleukin-7 receptor alpha gene).2 While the
etiology is unclear, current treatment options are used to reduce inflammation and prevent new
flare ups. Acute episodes are treated with steroids (methylprednisolone, prednisone, or
dexamethasone) to reduce inflammation.2 Current first line recommendations for relapse
prevention include interferon β-1a, interferon β-1b, glatiramer acetate, fingolimod,
teriflunomide, or dimethyl fumarate.2 If patients continue to have disease activity then providers
may consider using natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, or
mitoxanate.2 While these therapies aim to relieve symptoms and prevent relapse there is yet to be
a definitive curative treatment.
While patients may find relief from these medications, the cost of treatment is very
expensive. The annual cost for relapse prevention medications listed above range from $51,158
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to $ 63,806 annually.3 On top of drug costs, MS patients are 3.5 times as likely to be
hospitalized, twice as likely to have at least 1 emergency room visit and 2.4 times as likely to
have at least 1 visit for physical, occupational, or speech therapy. Not only do they seek care
more frequently than the average patient but they also spend more money on medical services. In
comparing patients with MS to non-MS patients, it was found that on average they spend on
$4,110 on inpatient services compared to $836, $1,693 vs. $259 for radiology services, $432 vs.
$189 for ER services, and $849 vs. $310 for office visits in a one-year period.4 These are only the
costs patients experience for one year and this is a life-long progressively disabling condition.
Patients with MS have more medical visits and expenses than the average patient.
There is no current cure for multiple sclerosis. The above medications are expensive and
do not alter the course of the condition. Mesenchymal stem cell therapy is a relatively new area
of research in treating MS and may be helpful in preventing relapses in affected patients. This
paper reviews two randomized control trials and a case series in evaluating if stem cells are a
new potential therapy as a treatment option for people suffering from MS.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not mesenchymal
stem cell therapy decreased the number of relapses in patients with multiple sclerosis.
METHODS
Two randomized control trials and one case series are included in this review. The
population consisted of males and females ages 18 and older with multiple sclerosis. Li J, Zhang
D, Geng T, et al. compared the number of relapses between a control group receiving steroid
treatment and the experimental group which received stem cell therapy. Both groups received the
same treatment schedule of IV methylprednisolone for 6 weeks but the experimental group
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received human umbilical cord derived mesenchymal stem cells (HUC-MSC) therapy three
times a week in addition to steroids.5 The number of relapses were then compared between the
two groups.5 Llufriu S, Sepulveda M, Blanco Y, et al study contained two randomized groups
that received either bone marrow derived mesenchymal stem cells (BM-MSC) IV for 6 months
or placebo. The treatment was reversed at 6 months and patients were followed for an additional
year. The authors compared the two groups at baseline, 6 months, and 1 year.6 Lu Z, Zhao H, Xu
J, Zhang Z, Zhang X, et al compared the relapse frequency in the same patient population before
and 18 months after a series of five injections of HUC-MSC.7
The studies were found searching PubMed for key words: multiple sclerosis,
mesenchymal stem cells. Articles were chosen based on their relevance to the proposed clinical
question and were selected only if they studied patient oriented evidence that matters (POEMs).
Articles were published in English in peer reviewed journals between 2006 and 2016.
Participants that were included in the studies were relapse-remitting multiple sclerosis (RRMS)
or secondary-progressive multiple sclerosis (SPMS)5,6,7, EDSS scores between 3.0 to 8.06, and
age between 18 and 657. Those excluded were patients with significant cardiac/renal/liver
failure5, active or chronic infection5,6,7, or autoimmune condition unrelated to MS7. The statistics
reported in this review include numbers needed to treat (NNT), confidence intervals, chi-squares,
mean difference, and p-values. See Table 1 for demographics and inclusion/exclusion criteria.
Table 1 – Demographics & Characteristics of Included Studies
Study

Type

Li5 (2014)

RCT

#
Age
Pts (yrs)
23 2555

Inclusion
Criteria
-RRMS or
SPMS
- Mean EDSS
of 5.0
-deterioration
of > 1.0 on

Exclusion Criteria

W/D Interventions

-treated with
cytotoxic
medications in the
past 3 months

0

Human
umbilical
cord-derived
mesenchymal
stem cell
therapy at the

Balliet, Stem Cell Therapy in MS 4
EDSS in past
year
-> 2 attacks
in the last 2
years

Llufriu6
(2014)

RCT

9

2348

Lu7 (2013)

Case 8
Series

1859

-RRMS not
responding
therapy for a
year
-ages 18 to 50
years
-disease
duration of 2
to 10 years
-EDSS scores
3.0 to 6.5.
-SPMS
-Ages 18-65
-Duration of
disease > 4
years
-EDSS score
3.0 to 8.0
-Failure to
respond to
the MS
therapy

-significant cardiac,
renal, or hepatic
failure
-active infection
-severe cognitive
decline
-unable to
understand and sign
the informed
consent
-Active or chronic
1
infection
-treatment with any
immunosuppressive
therapy within the
previous 3 months or
interferon-beta,
glatiramer acetate or
corticosteroids within
30 days prior to
randomization.
-Systemic active
0
disease
-Autoimmune
condition unrelated
to MS or allergies;
-Pregnant or
possibly pregnant;
-HIV (+), Tumor
marker (+), brain
tumor or BP ≥
200 mmHg/110
mmHg

same time as
antiinflammatory
treatment

Bone marrow
derived
mesenchymal
stem cells

intrathecal
intravenous
injections of
human
umbilical
cord-derived
stem cells

OUTCOMES MEASURED
Clinical outcomes included the number of relapses patients experienced measured by
onset of new neurological symptoms or by the presence of new gadolinium enhancing lesions
(GELs) on MRI.
RESULTS
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Li J, Zhang D, Geng T, et al. had an experimental group consisting of 13 patients with an
average age of 42 years and a control group of 10 patients with an average age of 39 years. All
patients had either RRMS or SPMSS. The experimental group had an average EDSS score of 7.0
and the control group had an average score of 6.0. All patients were treated with IV
methylprednisolone for 5 days followed by an oral prednisone taper for 2 weeks until they
reached the maintenance dosage (5mg daily). The experimental group received HUC-MSCs once
every 2 weeks 3 consecutive times. The authors used a chi-square to demonstrate that gender and
type of MS had no significant effect between groups (p = 0.968). A chi-square was also
performed on recurrence frequency data which found a significant decrease in relapse frequency
between the two groups (p < 0.038).5 The study suggests that using HUC-MSCs with steroid
therapy decreased relapses when compared to steroids alone.
This review further investigated the incidence of relapses by dichotomizing the data
found in Table 5 (Group x Relapse Incidence Crosstab) from Li J, Zhang D, Geng T, et al.
Success was defined as one relapse or less and failure was considered if a patient had more than
one relapse after treatment. This data was then constructed into a 2x2 table to calculate the
control event rate (CER), experimental event rate (EER), relative and absolute risk ratio (RRR),
absolute risk ratio (ABR), and numbers needed to treat (NNT). The results are summarized in
Table 2 below.
Table 2: Efficacy of HUC-MSC in Reducing Relapses Compared to Steroids
Study
Li5

CER
0.20

EER
0.77

RRR
2.85

ABR
0.57

NNT
2

Llufriu S, Sepulveda M, Blanco Y, et al. had a total of nine participants in their study,
four of which were randomized into the placebo group and five which received the BM-MSCs.
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The experimental group received 6 months of BM-MSC therapy and then the treatment was
reversed for the next six months. Patients were assessed at 1, 3, 6, 7, 9, and 12 months after
randomization. No difference was found in the demographics or gadolinium enhancing lesions at
baseline (4.75 + 7.6 vs 4.6 + 9.7, p = 1.0). At six months, the mean difference in cumulative GEL
was found to be difference when comparing the data at a 95% confidence interval (CI) (1.53,
95% CI 0.53-4.42 vs 6.15, 95% CI 2.19-17.28, p = 0.064). At the end of the study there was also
a decrease in mean number of GEL between the BM-MSC group and placebo group (-2.78 +
5.89 vs 3 + 5.36, p = 0.075). Four patients experienced relapses during the placebo phase. One
patient assigned to the placebo group withdrew consent after having five relapses within the first
three months. Three patients experienced relapses during the BM-MSC treatment period.6 While
the study showed a decrease none of the results were statistically significant.
This review dichotomized the data in Figure 2 (relapses and gadolinium-enhancing
lesions during the study) from Llufriu S, Sepulveda M, Blanco Y, et al. The number of relapses
were counted in placebo and MSC treatment groups. A 2x2 table was constructed comparing
before and after treatment with success defined as 1 relapse or less. Patient one withdrew from
treatment after having 3 relapses and his data was counted as a failure for both the placebo and
control groups. A 2x2 table was constructed and used to calculate CER, EER, RRR, ABR, and
NNT reported below in Table 3.
Table 3: Efficacy of BM-MSC in Reducing Relapses Compared to Placebo
Study
Llufriu6

CER
0.78

EER
0.78

RRR
0

ABR
0

NNT
0

Lu Z, Zhao H, Xu J, Zhang Z, Zhang X, et al. recruited eight patients with SPMS to
receive intrathecal IV injections of HUC-MSCs. The authors used brain and spinal MRI to
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evaluate any decrease in volume or number of lesions before and after treatment as well as any a
neurological assessment to detect any new neurological symptoms. The authors noted that the
GEL lesion volume was lower 12 months after treatment and that two patients had a decrease in
the number of lesions. The decreased GELs and reported symptoms were analyzed by using a
mean difference to compare the same group at baseline and after treatment. Their results
suggested that the relapse rate was reduced by 36.4% at 18 months post treatment compared to
before treatment (1.2 + 0.5 vs 3.3 + 0.7, p < 0.05).7 The number of relapses before and after
treatment are summarized in Table 4 below.
Table 4: Efficacy of HUC-MSC in Reducing Relapses Before and After Treatment
Study

Relapses
Relapses
Before HUC- After HUCMSC
MSC

Lu7

25

9

Mean
Relapses
Before
HUCMSC
3.3 + 0.7

Mean
Relapses
After
HUCMSC
1.2 + 0.5

P-value

Relapse
Frequency

0.05

36.4%

DISCUSSION
Stem cell therapy is a promising new area of research for multiple chronic nervous
disorders. Stem cells can be harvested from the bone marrow of healthy donors (BM-MSC) or
from umbilical cord blood (HUS-MSC). Patients are treated with a preparative regiment to
suppress the patient’s immune system. Immunosuppression with cyclosporine or tacrolimus is
used to prevent graph versus host disease.8 Stem cells are used in this manner to currently
provide curative treatments for leukemias, myelodysplasia, and severe aplastic anemia.8
Umbilical cord stem cells are associated with less graft versus host disease, less HLA restriction,
and less likely to be contaminated with herpes virus compared to other forms of stem cells.9
HUS-MSCs are preferred over BM-MSC due to more availability and less risk of graft versus
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host disease. Many clinical trials are being undertaken in other neuronal conditions such as ALS,
spinal cord injury, epilepsy, Parkinson’s disease, and Alzheimer’s disease.9 Stem cells are
currently being studied as a new therapy in the treatment of progressive degenerative
neurological diseases.
Stem cell therapy is not without its own risks. Most studies report very little side effects
and demonstrate a good safety profile for the drug. Out of the three studies in this review none
reported any adverse reactions to the therapy. Herberts, Kwa, and Hermsen10 reviewed adverse
reactions to stem cell therapy and found the following: rejection of cells, susceptibility to
disease, toxicity, neoplasm formation, disease transmission, and reactivation of latent viruses.
The most concerning of which is tumor formation. They followed a report of a 13-year-old boy
developing a brain tumor of non-host origin four years after transplant. This is thought be due to
the resemblance of stem cells to cancer cells with a long-life span, apoptosis resistance, and
ability to replicate for long periods of time.10 The largest concern with stem cell therapy is
neoplasm formation which may be a future area of research in the long-term safety profile of this
novel therapy.
In the United States, the government has authorized research for using existing
embryonic stem cells but restricts federal funding for developing new stem cell lines. Stem cell
research raises concerns on the ethical limits of science and human life. A team of scientists,
health care providers, lawyers, and sociologists must balance the medical benefits with the
ethical dilemmas of stem cell therapy.10 Other limitations surrounding stem cell therapy include
not being in clinical phases and not being a FDA approved therapy. Therefore, stem cell therapy
is not readily available yet as a treatment option is still in preclinical research phases.
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In the three articles reviewed each found that stem cells decreased relapse rates. Li J,
Zhang D, Geng T, et al. demonstrated that recurrence frequency was significantly different
between the two groups (p < 0.038).5 Table 2 evaluated this data as NNT showing that for every
two patients treated with human umbilical cord derived mesenchymal stem cell therapy for 6
weeks, 2 or more relapses were prevented when compared to the control group. This is a small
treatment effect that could become more significant with a larger pool of patients. Llufriu S,
Sepulveda M, Blanco Y, et al. found a nonsignificant decrease in mean number of GEL between
the BM-MSC group and placebo group (-2.78 + 5.89 vs 3 + 5.36, p = 0.075).6 Table 3 evaluated
the number of relapses as a NNT; For every patient with multiple sclerosis treated with bone
marrow derived stem cells for 12 months, no additional relapses will be prevented when
compared to the placebo group. This may be due to the stringent criteria used to dichotomize the
data; defining a success as one relapse or less. It is also due in part to the small sample size of
nine patients. Lu Z, Zhao H, Xu J, Zhang Z, Zhang X, et al. found a reduction in relapse rate by
36.4% at 18 months post treatment compared to before treatment (1.2 + 0.5 vs 3.3 + 0.7, p <
0.05).7 All three studies found a decrease in the number of relapses participants experienced after
treatment with mesenchymal stem cells however one of the RCTs did not translate well as NNT
and was not statistically significant.
This EBM review encountered difficulty in finding appropriate studies and each study
found was limited by a small sample size. Only two RCTs and one case series were found using
online databases for mesenchymal stem cell therapy giving limited the available data to be
reviewed. Each article found had small sample sizes decreasing the generalizability of the
results. More research is necessary to confirm the validity of these authors’ results and a larger
participant group is needed to help generalize the results. Furthermore, the articles followed
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participants for about a year which is a short amount of time for a chronic condition such as MS.
It is unknown how long the stem cells remain effective for or the frequency of treatments needed
to prevent relapses and an area that needs future investigation. The case series lacks
randomization, blinding, and a comparison group making it difficult to make any generalizations
about the effectiveness of MSCs. Also, none of the studies compared biologic therapy to MSC
therapy. The authors only compared MSC therapy to placebo, steroids, and no treatment. It is
unknown if MSC therapy is superior to biologics in preventing relapses in MS patients. Further
research is needed to address these issues.
CONCLUSION
The results of two RCTs and one case studies showed a decrease in the number of
relapses patients with MS experienced after being treated with MSCs compared to steroids,
placebo, and before therapy. However, in evaluating Llufriu et al’s study as NNT, it was found
that for every patient with multiple sclerosis treated with bone marrow derived stem cells for 12
months, no additional relapses will be prevented when compared to the placebo group. Each
study suffered from having a very small group of participants making it difficult to generalize the
results. Repeat research is warranted with larger population sizes to support the evidence found
in this review. The case series data is limited due to a lack of randomization, blinds, and a
control group. The only research that focused on POEM was performed in comparing MSC
therapy to placebo and steroids. Steroid therapy is only used for relief of acute exacerbations of
MS and not for relapse prevention. This does not demonstrate any advantage to current therapies
to keep MS in remission and needs to be addressed before becoming a treatment option available
to patients. This review suggests that further research is warranted to compare MSC therapy to
biologic therapies such as interferon, fingolimod, or glatiramer acetate. Further research is
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necessary to help evaluate the efficacy of MSC therapy as a viable treatment option for patients
suffering from MS.
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